^
    Back
    Association details:
    Biomarker:HER-2 underexpression
    Cancer:Gastric Cancer
    Drug:Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Breast Cancer)
    New
    Title:

    Enhertu approved in China as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer

    Excerpt:
    AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy....The approval by China’s National Medical Products Administration (NMPA) is based on the results of the DESTINY-Breast04 Phase III trial...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

    Excerpt:
    ...- Advanced breast cancer with HER2 low expression that is refractory to or intolerable with standard treatment, or for which...
    Trial ID:
    DS8201-A-J101
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2021
    Title:

    Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells

    Published date:
    03/10/2021
    Excerpt:
    Our results indicate that T-DXd shows efficacy in HER2-amplified GC cell lines, HER2 moderate/low-expression, and some cell lines with HER2 non-expression.